Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is reporting on its dosage and time-release ketamine-loaded implant, which is designated as SP-26. The implant is being developed through a collaboration between Silo Pharma and Sever Pharma Solutions. Currently, SP-26 is advancing through analytical testing and small-batch, preclinical, proof-of-concept extrusion trials to determine drug release and stability. The announcement noted that the companies have received positive compliance inspections from the state and federal Drug Enforcement Administration (‘DEA’) authorities, resulting in Sever Pharma Solutions now being able to begin working with ketamine and loading it into the implant. The company observed that the dosage and time-release formulation for the implant would be studied using the subcutaneous injection method. “Many chronic pain sufferers are seeking a nonopioid treatment that offers relief,” said Silo Pharma CEO Eric Weisblum in the press release. “Based on findings to date, we believe SP-26 has the potential to be the first at-home approved ketamine treatment for chronic pain including fibromyalgia.”
To view the full press release, visit https://ibn.fm/zyNqU
About Silo Pharma Inc.
Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as Alzheimer’s, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN